Objective: Indications of bioprosthetic mitral valve replacement. Short and medium – term clinical, echocardiography outcomes of bioprosthetic mitral valve replacement in Heart Instutute Ho Chi Minh City from 1/2010 to 12/2015. Methods: Retrospective and prospective studies, longitudinal monitoring. Study period from 1/2010 to 12/2015 with a total of 95 consecutive patients, who underwent bioprosthetic mitral valve replacement surgery at Heart Institute Ho Chi Minh City. Results: The mean age was 51,8 ± 15,4; 50 – 65 years old (43,2%), patients > 65 years

old (17,9%), and patients < 50 years old (38,9%) (mainly female of reproductive ages with 94,6%. Before surgery: NYHA II (76,8%), NYHA III (21,1%),

NYHA IV (2,1%). Most of the indications of bioprosthetic mitral valve replacement were at IC and IB. The valve types were Epic Saint Jude (56,8%) and Carpentier – Edwards (41,1%). The mean biological mitral valve size was 26,2 ± 1,3 mm; valve size 25 mm (48,4%), 27 mm (42,1%) and 29 mm (9,5%).

Coronary angiography before surgery (63,2%); most patients over 40 years old (84,5%), ejection fractions

≤ 50% had coronary angiography. Severe coronary artery stenosis (21,7%) mostly underwent coronary artery bypass surgery (84,6%). Complications: short- term with BAV III requiring permanent pacemaker 1 (1,1%), infectious endocarditis causing paravalvular

regurgitation requiring reoperation 1 (1,1%), biological mitral valve thrombosis with one (1,1%), leaky biological mitral valve with one (1,1%); medium-term with biological mitral valve thrombosis with one (1,1%), paravalvular regurgitation with one (1,1%). Short and medium – term mortality with one (1,1%) and three (3,2%). Clinically, most of the patients no symptoms of heart failure, short-term (83%), medium- term (94,5%), left atrial sizes and systolic pulmonary pressure significantly improved (p < 0,001), bioprosthetic mitral valves works well, no valve degeneration in the medium-term follow-up. Conclusions: Bioprosthetic mitral valve replacement is mainly performed in elderly patients and women of reproductive ages. Indications of bioprosthetic mitral valve replacement is mostly IC and IC. The most commonly used bioprosthetic mitral valve types were Epic Saint Jude and Carpentier – Edwards. The mean biological mitral valve size were 26,2 ± 1,3 mm. Coronary angiography before surgery in elderly patients, reduced ejection fraction, risk factors for coronary artery disease. Short and medium-term clinical results, low complications, almost no symptoms of heart failure; bioprosthetic mitral valves work well, the size of left atrium and systolic pulmonary pressure improved